Diabetic Neuropathy Modeling Services
The complex pathological mechanisms of diabetic neuropathy pose significant challenges for novel drug development. Leveraging extensive expertise in diabetes research, Ace Therapeutics has developed a series of reliable preclinical models for diabetic neuropathy. Our robust and consistent models are designed to provide powerful and dependable tools for drug screening, efficacy evaluation, and mechanism studies, accelerating the development of innovative therapies.
Why are Reliable Models for Diabetic Neuropathy Critical?
- The complexity of mechanism exploration: Unraveling the molecular mechanisms underlying neuronal damage, axonal degeneration, and myelin abnormalities under hyperglycemic conditions requires models capable of recapitulating human disease progression.
- The bottleneck in drug efficacy evaluation: Effective drug development relies on objective metrics that accurately reflect symptomatic improvements, such as relief from neuropathic pain, restoration of nerve conduction velocity, and regeneration of nerve fibers.
- Multi-stage validation: Drug development for diabetic neuropathy requires progression through target validation, candidate drug screening, and efficacy assessment. Precise disease models serve as a critical tool for identifying effective therapeutics while eliminating non-viable candidates, significantly reducing the risk of clinical development failure.
Our Diabetic Neuropathy Modeling Services
We provide customed in vivo and in vitro models of diabetic neuropathy to assist clients in efficacy screening and evaluation.
- Animal Modeling by Lesion Type
| Model Name |
Description |
| Peripheral Neuropathy Models |
- STZ-induced T1DM models
- High-fat diet combined with low-dose STZ-induced T2DM models
- Spontaneous T2DM models (db/db or ob/ob)
|
| Autonomic Neuropathy Models |
Long-term diabetes model derivation (cardiovascular & gastrointestinal autonomic function assessment) |
| Central Nervous System Pathology Model |
Modeling central nervous system involvement phenotypes in diabetes, such as cognitive dysfunction and cerebrovascular injury. |
- Diabetic Neuropathy Modeling by Model Species
| Model Species |
Description |
| Rodent Models |
Including mouse (db/db, ob/ob, STZ-induced, etc.) and rat (STZ-induced, ZDF rat, etc.) models. Cost-controllable and easy to operate, suitable for high-throughput drug screening. |
| Non-human Primate Models |
Utilizing species such as cynomolgus monkeys, these models exhibit pathological features that more closely resemble human diabetic neuropathy and are suitable for preclinical efficacy validation of candidate drugs. |
- Customized Model Development Services
We provide tailored solutions for diabetic neuropathy models based on clients' research requirements.
- Model Validation Services
We concurrently provide model phenotype validation services, including neuro-electrophysiological testing, sensory function assessment, histopathological analysis of nerve tissues, and detection of relevant biomarkers (such as inflammatory factors and oxidative stress markers), to ensure model validity.
Our Advanced Technology Platform
- Animal Model Development and Breeding Platform
Featuring SPF-grade animal laboratories equipped with specialized breeding facilities and dedicated husbandry teams, we consistently establish multiple standardized models of diabetic neuropathy while supporting model propagation and strain preservation.
- Phenotype Precision Detection Platform
Equipped with neurophysiological instruments, behavioral testing devices (such as thermal pain threshold testers and mechanical pain threshold testers), and histopathological analysis systems, it enables comprehensive evaluation of neurological function, morphological features, and molecular-level pathological characteristics.
- Biomarker Analysis Platform
Integrating technologies such as ELISA, qPCR, Western Blot, and flow cytometry, this platform detects core biomarkers including neuropathy-associated inflammatory factors, neurotrophic factors, and oxidative stress molecules, supporting model validation and mechanism studies.
The core team at Ace Therapeutics comprises diabetes specialists, animal model researchers, and pathologists with extensive project experience, providing expert technical consultation and program optimization. We deliver integrated end-to-end services covering model design, construction, validation, and final data delivery. Please contact us for more detailed information.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
